Cargando…

HbA1c during early pregnancy reflects beta-cell dysfunction in women developing GDM

INTRODUCTION: It is of current interest to assess eligibility of hemoglobin A1c (HbA1c) as a screening tool for earlier identification of women with risk for more severe hyperglycemia in pregnancy but data regarding accuracy are controversial. We aimed to evaluate if HbA1c mirrors pathophysiological...

Descripción completa

Detalles Bibliográficos
Autores principales: Bozkurt, Latife, Göbl, Christian S, Leitner, Karoline, Pacini, Giovanni, Kautzky-Willer, Alexandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7607595/
https://www.ncbi.nlm.nih.gov/pubmed/33132213
http://dx.doi.org/10.1136/bmjdrc-2020-001751
_version_ 1783604671542198272
author Bozkurt, Latife
Göbl, Christian S
Leitner, Karoline
Pacini, Giovanni
Kautzky-Willer, Alexandra
author_facet Bozkurt, Latife
Göbl, Christian S
Leitner, Karoline
Pacini, Giovanni
Kautzky-Willer, Alexandra
author_sort Bozkurt, Latife
collection PubMed
description INTRODUCTION: It is of current interest to assess eligibility of hemoglobin A1c (HbA1c) as a screening tool for earlier identification of women with risk for more severe hyperglycemia in pregnancy but data regarding accuracy are controversial. We aimed to evaluate if HbA1c mirrors pathophysiological precursors of glucose intolerance in early pregnancy that characterize women who develop gestational diabetes mellitus (GDM). RESEARCH DESIGN AND METHODS: 220 pregnant women underwent an HbA1c measurement as well as an oral glucose tolerance test (OGTT) with multiple measurements of glucose, insulin and C-peptide for evaluation of insulin sensitivity and beta-cell function at 16th gestational week (IQR: 14–18). Clinical follow-ups were performed until end of pregnancy. RESULTS: Increased maternal HbA1c ≥5.7% (39 mmol/mol) corresponding to pre-diabetes outside of pregnancy was associated with altered glucose dynamics during the OGTT. Pregnancies with early HbA1c ≥5.7% showed higher fasting (90.4±13.2 vs 79.7±7.2 mg/dL, p<0.001), mean (145.6±31.4 vs 116.2±21.4 mg/dL, p<0.001) as well as maximum glucose concentrations and tended to a delay in reaching the maximum glucose level compared with those with normal-range HbA1c (186.5±42.6 vs 147.8±30.1 mg/dL, p<0.001). Women with increased HbA1c showed impaired beta-cell function and differences in disposition index independent of body mass index status. We observed a high specificity for the HbA1c cut-off of 5.7% for GDM manifestation (0.96, 95% CI 0.91 to 0.98) or need of glucose-lowering medication (0.95, 95% CI 0.90 to 0.98) although overall predictive accuracy was moderate to fair. Further, elevated HbA1c was associated with higher risk for delivering large-for-gestational-age infants, also after adjustment for GDM status (OR 4.4, 95% CI 1.2 to 15.0, p=0.018). CONCLUSIONS: HbA1c measured before recommended routine screening period reflects early pathophysiological derangements in beta-cell function and glucose disposal that are characteristic of GDM development and may be useful in early risk stratification.
format Online
Article
Text
id pubmed-7607595
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-76075952020-11-12 HbA1c during early pregnancy reflects beta-cell dysfunction in women developing GDM Bozkurt, Latife Göbl, Christian S Leitner, Karoline Pacini, Giovanni Kautzky-Willer, Alexandra BMJ Open Diabetes Res Care Cardiovascular and Metabolic Risk INTRODUCTION: It is of current interest to assess eligibility of hemoglobin A1c (HbA1c) as a screening tool for earlier identification of women with risk for more severe hyperglycemia in pregnancy but data regarding accuracy are controversial. We aimed to evaluate if HbA1c mirrors pathophysiological precursors of glucose intolerance in early pregnancy that characterize women who develop gestational diabetes mellitus (GDM). RESEARCH DESIGN AND METHODS: 220 pregnant women underwent an HbA1c measurement as well as an oral glucose tolerance test (OGTT) with multiple measurements of glucose, insulin and C-peptide for evaluation of insulin sensitivity and beta-cell function at 16th gestational week (IQR: 14–18). Clinical follow-ups were performed until end of pregnancy. RESULTS: Increased maternal HbA1c ≥5.7% (39 mmol/mol) corresponding to pre-diabetes outside of pregnancy was associated with altered glucose dynamics during the OGTT. Pregnancies with early HbA1c ≥5.7% showed higher fasting (90.4±13.2 vs 79.7±7.2 mg/dL, p<0.001), mean (145.6±31.4 vs 116.2±21.4 mg/dL, p<0.001) as well as maximum glucose concentrations and tended to a delay in reaching the maximum glucose level compared with those with normal-range HbA1c (186.5±42.6 vs 147.8±30.1 mg/dL, p<0.001). Women with increased HbA1c showed impaired beta-cell function and differences in disposition index independent of body mass index status. We observed a high specificity for the HbA1c cut-off of 5.7% for GDM manifestation (0.96, 95% CI 0.91 to 0.98) or need of glucose-lowering medication (0.95, 95% CI 0.90 to 0.98) although overall predictive accuracy was moderate to fair. Further, elevated HbA1c was associated with higher risk for delivering large-for-gestational-age infants, also after adjustment for GDM status (OR 4.4, 95% CI 1.2 to 15.0, p=0.018). CONCLUSIONS: HbA1c measured before recommended routine screening period reflects early pathophysiological derangements in beta-cell function and glucose disposal that are characteristic of GDM development and may be useful in early risk stratification. BMJ Publishing Group 2020-11-01 /pmc/articles/PMC7607595/ /pubmed/33132213 http://dx.doi.org/10.1136/bmjdrc-2020-001751 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Cardiovascular and Metabolic Risk
Bozkurt, Latife
Göbl, Christian S
Leitner, Karoline
Pacini, Giovanni
Kautzky-Willer, Alexandra
HbA1c during early pregnancy reflects beta-cell dysfunction in women developing GDM
title HbA1c during early pregnancy reflects beta-cell dysfunction in women developing GDM
title_full HbA1c during early pregnancy reflects beta-cell dysfunction in women developing GDM
title_fullStr HbA1c during early pregnancy reflects beta-cell dysfunction in women developing GDM
title_full_unstemmed HbA1c during early pregnancy reflects beta-cell dysfunction in women developing GDM
title_short HbA1c during early pregnancy reflects beta-cell dysfunction in women developing GDM
title_sort hba1c during early pregnancy reflects beta-cell dysfunction in women developing gdm
topic Cardiovascular and Metabolic Risk
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7607595/
https://www.ncbi.nlm.nih.gov/pubmed/33132213
http://dx.doi.org/10.1136/bmjdrc-2020-001751
work_keys_str_mv AT bozkurtlatife hba1cduringearlypregnancyreflectsbetacelldysfunctioninwomendevelopinggdm
AT goblchristians hba1cduringearlypregnancyreflectsbetacelldysfunctioninwomendevelopinggdm
AT leitnerkaroline hba1cduringearlypregnancyreflectsbetacelldysfunctioninwomendevelopinggdm
AT pacinigiovanni hba1cduringearlypregnancyreflectsbetacelldysfunctioninwomendevelopinggdm
AT kautzkywilleralexandra hba1cduringearlypregnancyreflectsbetacelldysfunctioninwomendevelopinggdm